Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing first-in-class allogeneic gamma delta T
cell therapies for cancer and other diseases, today announced that
Chen Schor, President and Chief Executive Officer and Stewart
Abbot, Ph.D., Chief Scientific and Operating Officer, will
participate in a fireside chat at The JMP Securities Hematology
Summit on Tuesday, December 15, 2020 at 2:00 PM ET.
A live audio webcast of the fireside chat can be accessed on the
Investors section of Adicet Bio’s website at
https://investor.adicetbio.com. An archived replay will be
available for 30 days following the presentation.
About Adicet Bio, Inc.Adicet Bio, Inc. is a
biotechnology company discovering and developing allogeneic gamma
delta T cell therapies for cancer and other diseases. Adicet is
advancing a pipeline of “off-the-shelf” gamma delta T cells,
engineered with chimeric antigen receptors and T cell receptor-like
antibodies to enhance selective tumor targeting, facilitate innate
and adaptive anti-tumor immune response, and improve persistence
for durable activity in patients. For more information, please
visit our website at http://www.adicetbio.com.
Adicet Bio., Inc.Investor and Media
Janhavi MohiteStern Investor Relations,